Design and synthesis of prolylcarboxypeptidase (PrCP) inhibitors to validate PrCP as a potential target for obesity

Journal of Medicinal Chemistry

Volumn 53, Issue 19, 2010, Pages 7251-7263

  Zhou, Changyou ^a   Garcia Calvo, Margareta ^a   Pinto, Shirly ^a   Lombardo, Matthew ^a   Feng, Zhe ^a   Bender, Kate ^a   Pryor, Kellyann D ^a   Bhatt, Urmi R ^a   Chabin, Renee M ^a   Geissler, Wayne M ^a   Shen, Zhu ^a   Tong, Xinchun ^a   Zhang, Zhoupeng ^a   Wong, Kenny K ^a   Roy, Ranabir Sinha ^a   Chapman, Kevin T ^a   Yang, Lihu ^a   Xiong, Yusheng ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL] 3 (3 PHENYL 1,2,4 OXADIAZOL 5 YL)PROPAN 1 ONE; 2 AMINO 3 (BIPHENYL 4 YL) 1 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL]PROPAN 1 ONE; 3 (2' METHYLBIPHENYL 4 YL) 1 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL]PROPAN 1 ONE; 3 (3' AMINOBIPHENYL 4 YL) 1 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL]PROPAN 1 ONE; 3 (BIPHENYL 4 YL) 1 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYROLIDIN 1 YL]PROPAN 1 ONE; 3 [[(9H FLUOREN 9 YLMETHOXY)CARBONYL]AMINO] 4 OXO 4 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL]BUTANOIC ACID; 4 [[(9H FLUOREN 9 YLMETHOXY)CARBONYL]AMINO] 5 OXO 5 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL]PENTANOIC ACID; 4' [2-[(TERT BUTOXYCARBONYL)AMINO] 3 OXO 3 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL]PROPYL]BIPHENYL 4 CARBOXYLIC ACID; 9H FLUOREN 9 YLMETHYL [1 OXO 1 [(2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL]BUTAN 2 YL]CARBAMATE; 9H FLUOREN 9 YLMETHYL [1 OXO 1 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL]OCTAN 2 YL]CARBAMATE; 9H FLUOREN 9 YLMETHYL [1 OXO 5 PHENYL 1 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL]PENTAN 2 YL]CARBAMATE; 9H FLUOREN 9 YLMETHYL [3 (BENZYLOXY) 1 OXO 1 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL]PROPAN 2 YL]CARBAMATE; 9H FLUOREN 9 YLMETHYL[3 (BIPHENYL 4 YL) 1 OXO 1 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL]PROPAN 2 YL]CARBAMATE; 9H FLUOREN 9 YLMETHYL[3 HYDROXY 1 OXO 1 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL]PROPAN 2 YL]CARBAMATE; 9H FLUOREN 9 YLMETHYL[4 (METHYLSULFANYL) 1 OXO 1 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL]BUTAN 2 YL]CARBAMATE; 9H FLUOREN 9 YLMETHYL[4 (METHYLSULFONYL) 1 OXO 1 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL]BUTAN 2 YL]CARBAMATE; 9H FLUOREN 9 YLMETHYL[5 AMINO 1 OXO 1 [2 (4 PHENYL 1H IMIDAZOL 2 YL)]PENTAN 2 YL]CARBAMATE; 9H FLUOREN 9 YLMETHYL[6 AMINO 1 OXO 1 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL]HEXAN 2 YL]CARBAMATE; 9H FLUOREN 9 YLMETHYL[6 AMINO 1 OXO 1 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1YL]HEXAN 2 YL]CARBAMATE; BENZYL [5 [[(9H FLUOREN 9 YLMETHOXY)CARBONYL]AMINO] 6 OXO 6 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL]HEXYL]CARBAMATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; N [3 (BIPHENYL 4 YL) 1 OXO 1 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL]PROPAN 2 YL] 3,3 DIMETHYLBUTANAMIDE; N[1 OXO 1 [2 (5 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL]HEXAN 2 YL]ACETAMIDE; PROLINE CARBOXYPEPTIDASE; PROLINE CARBOXYPEPTIDASE INHIBITOR; PROP 2 EN 1 YL [5 [[(9H FLUOREN 9 YLMETHOXY)CARBONYL]AMINO] 6 OXO 6 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1YL]HEXYL]CARBAMATE; SERINE PROTEINASE; TERT BUTYL 7 [[(9H FLUOREN 9 YLMETHOXY)CARBONYL]AMINO]8 OXO 8 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL]OCTANOATE; TERT BUTYL[3 (BIPHENYL 4 YL) 1 OXO 1 [2 (4 PHENYL 1H IMIDAZOL 2 YL)PYRROLIDIN 1 YL]PROPAN 2 YL]CARBAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; 2-AMINO-N-(3-(BIPHENYL-4-YL)-1-(2-(5,6-DICHLORO-1H-BENZIMIDAZOL-2-YL)PYRROLIDIN-1-YL)-1-OXOBUTAN-2-YL)-2-METHYLPROPANAMIDE; ANTIOBESITY AGENT; BENZIMIDAZOLE DERIVATIVE; CARBOXYPEPTIDASE; LYSOSOMAL PRO-X CARBOXYPEPTIDASE; PHENYLALANINE; PLASMA PROTEIN; PROTEIN BINDING; SERINE PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; ASYMMETRIC SYNTHESIS; CHIRALITY; CONTROLLED STUDY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50; MALE; METABOLIC REGULATION; MOUSE; NONHUMAN; OBESITY; PROTEIN BINDING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; ENZYMOLOGY; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTI-OBESITY AGENTS; BENZIMIDAZOLES; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; CARBOXYPEPTIDASES; DRUG DESIGN; HUMANS; MALE; MICE; MICE, KNOCKOUT; OBESITY; PHENYLALANINE; PROTEIN BINDING; SERINE PROTEINASE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77957908834     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101013m     Document Type: Article

References (42)

1. Yang, H. Y. T.; Erdos, E. G.; Chiang, T. S. New enzymatic route for the inactivation of angiotensin Nature 1968, 218, 1224-1226
2. Yang, H. Y. T.; Erdos, E. G.; Chiang, T. S.; Jenssen, T. A.; Rodgers, J. G. Characteristics of an enzyme that inactivates angiotensin II (angiotensinase C) Biochem. Pharmacol. 1970, 19, 1201-1211
3. Odya, C. E.; Marinkovic, D. V.; Hammon, K, J.; Stewart, T. A.; Erdos, E. G. Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney J. Biol. Chem. 1978, 253 (17) 5927-5931
4. Skidgel, R. A.; Erdos, E. G. Cellular carboxypeptidases Immun. Rev. 1998, 161, 129-141
5. Kumamoto, K.; Stewart, T. A.; Johnson, A. R.; Erdos, E. G. Prolylcarboxypeptidase (angiotensinase C) in human lung and cultured cells J. Clin. Invest. 1981, 67, 210-215
6. Tan, F.; Morris, P. W.; Skidgel, R. A.; Erdos, E. G. Sequencing and cloning of human prolylcarboxypeptidase (angiotensinase C) J. Biol. Chem. 1993, 268 (22) 16631-16638
7. Miller, J. J.; Changaris, D. G.; Levy, R. S. Angiotensin carboxypeptidase activity in urine from normal subjects and patients with kidney damage Life Sci. 1991, 48, 1529-1535
8. Shariat-Madar, Z.; Mahdi, F.; Schmaier, A. H. Identification and Characterization of Prolylcarboxypeptidase as an Endothelial Cell Prekallikrein Activator J. Biol. Chem. 2002, 277 (20) 17962-17969 (Pubitemid 34967607)
9. Shariat-Madar, Z.; Mahdi, F.; Schmaier, A. H. Recombinant prolylcarboxypeptidase activates plasma prekallikrein Blood 2004, 103 (12) 4554
10. Wallingford, N.; Perround, B.; Gao, Q.; Coppola, A.; Gyengesi, E.; Liu, Z. W.; Gao, X. B.; Diament, A.; Haus, K. A.; Shariat-Madar, Z.; Hahdi, F.; Wardlaw, S. L.; Schmaier, A. H.; Warden, C. H.; Diano, S. Prolylcarboxypeptidase regulates food intake by inactivating α-MSH in rodents J. Clin. Invest. 2009, 119 (8) 2291-2303
11. Mallela, J.; Yang, J.; Shariat-Madar, Z. Prolylcarboxypeptidase: a cardioprotective enzyme Int. J. Biochem. Cell Biol. 2009, 41, 477-481
12. Wang, L.; Feng, Y.; Zhang, Y.; Zhou, H.; Jiang, S.; Niu, T.; Wei, J. L.; Xu, X.; Xu, X. P.; Wang, X. Prolylcarboxypeptidase gene, chronic hypertension, and risk of preeclampsia Am. J. Obstet. Gynecol. 2006, 195, 162-171
13. Shariat-Madar, B.; Kolte, D.; Verlangiert, A.; Shariat-Madar, Z. Prolylcarcarboxypeptidase (PRCP) as a new target for obesity treatment Diabetes, Metab. Syndr. and Obes.: Targets Ther. 2010, 3, 67-78
14. Diament, A. L.; Warden, C. H. Multiple linked mouse chromosome 7 loci influence body fat mass Int. J. Obes. 2004, 28, 199-210
15. Ngo, M. L.; Mahdi, F.; Kolte, D.; Shariat-Madar, Z. Upregulation of prolylcarboxypeptidase (PRCP) in lipopolysaccharide (LPS) treated endothelium promotes inflammation. J. Inflamm. 2009, 6, 3.
16. Burk, M. J.; Gross, M. F.; Martinez, J. P. Asymmetric Catalytic Synthesis of β-Branched Amino Acids via Highly Enantioselective Hydrogenation Reactions J. Am. Chem. Soc. 1995, 117, 9375
17. Nugent, W. A.; Feaster, J. E. Practical Synthesis of Methyl Z -2-(N -acetylamino)But-2-enoate. An Intermediate to d-and l -2-Aminobutyric Acid Synth. Commun. 1998, 28 (9) 1617-1623
18. Coleman, R. S.; Carpenter, A. J. Stereoselective bromination of dehydroamino acids with controllable retention or inversion of olefin configuration J. Org. Chem. 1993, 58, 4452-4461
19. Maryanoff, B. E. Inhibitors of Serine Proteases as Potential Therapeutic Agents: The Road from Thrombin to Tryptase to Cathepsin J. Med. Chem. 2004, 47 (4) 769
20. Edwards, P. D.; Meyer, E. F.; Vijayalakshmi, J.; Tuthill, P. A.; Andisik, D. A.; Gomes, B.; Strimpler, A. Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl α-Ketobenzoxazoles, and the X-Ray Crystal Structure of the Covalent Complex between Porcine Pancreatic Elastase and Ac-Ala-Pro-Val-2-Benzoxazole J. Am. Chem. Soc. 1992, 114 (5) 1854-1863
21. Jarho, E. M.; Vanalainen, J. I.; Poutiainen, S.; Leskinen, H.; Vespsalainen, J.; Christiaans, J. A. M.; Forsberg, M. M.; Mannisto, P. T.; Wallen, E. A. A., 2(S)-(Cycloalk-1-enecarbonyl)-1-(4-phenylbutanoyl)pyrrolidines and 2(S)-(aroyl)-1-(4-phenylbutanoyl)pyrrolidines as prolyl oligopepetidase inhibitors, Bioor, Med. Chem. 2007, 15, 2024 - 2031, and references therein.
22. Kanal, K.; Aranyi, P.; Bocskei, Z.; Ferenczy, G.; Harmat, V.; Simon, K.; Batori, S.; Nary-Szabo, G.; Hermecz, I. Prolyl oligopeptidase inhibition by N -acyl-pro-pyrrolidine-type molecules J. Med. Chem. 2008, 51, 7514-7522
23. Tsutsumi, S.; Okonogi, T.; Shibahara, S.; Ohuchi, S.; Hatsushiba, E.; Patchett, A. A.; Christensen, B. G. Synthesis and Structure-Activity Relationships of Peptidyl α-Keto Heterocycles as Novel Inhibitors of Prolyl Endopeptidase J. Med. Chem. 1994, 37 (21) 3492-502
24. Niestroj, A. I.; Heiser, U.; Schulz, I.; Rahfeld, J. U.; Bar, J.; Demuth, H. U.; Novel Compounds for the treatment of neurological disorders. Patent WO 2006058720, 2006.
25. Schechter, I.; Berge, A. On the size of the active site of proteases. I. Papain Biochem. Biophys. Res. Commun. 1967, 27, 157-162
26. Sanderson, P. E. J. Small, Noncovalent Serine Protease Inhibitors Med. Res. Rev. 1999, 19, 179-197
27. Patchett, A. A.; Nargund, R. P.; Tata, J. R.; Chen, M. H.; Barakat, K. J.; Johnston, D. B. R.; Cheng, K.; Chan, W. W. S.; Butler, B.; Hickey, G.; Jacks, T.; Schleim, K.; Pong, S. S.; Chaung, L. Y. P.; Chen, H. Y.; Frazier, E.; Leung, K. H.; Chiu, S. H. L.; Smith, R. G. Design and biological activities of L-163,191 (MK-0677): a potent orally active growth hormone secretagogue Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 7001-7005
28. Trainor, G. L. The importance of plasma protein binding in drug discovery Expert Opin. Drug Discovery 2007, 2 (1) 51-64
29. Copeland, R. A. Determination of serum protein binding affinity of inhibitors from analysis of concentration-response plots in biochemical activity assays J. Pharm. Sci. 2000, 89 (8) 1000-1007
30. 50 shift analysis for in vitro assays Bioorg. Med. Chem. Lett. 2004, 14 (4) 2309-2312
31. Visy, J.; Fitos, I.; Mady, G.; Urge, L.; Krajcsi, P.; Simonyi, M. Enantioselective plasma protein binding of bimoclomol Chirality 2002, 14, 638-642
32. Xu, J.; Wei, L.; Mathvink, R.; He, J.; Park, Y.-J.; He, H.; Leiting, B.; Lyons, K. A.; Marsilio, F.; Patel, R. A.; Wu, J. K.; Thornberry, N. A.; Weber, A. E. Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 2005, 15, 2533-2536
33. Edmondson, S. E.; Mastracchio, A.; Duffy, J. L.; Eiermann, G. J.; He, H.; Ita, I.; Leiting, B.; Leone, J. F.; Lyons, K. A.; Makarewicz, A. M.; Patel., R. A.; Petrov, A.; Wu, J. K.; Thornberry, N. A.; Weber, A. E. Discovery of potent and selective orally bioavailable b-substituted phenylalanine derivatives dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 2005, 15, 3048-3052
34. Rosenblum, J. S.; Kozarich, J. W. Prolyl Peptidases: A Serine Protease Subfamily with High Potential for Drug Discovery Curr. Opin. Chem. Biol. 2003, 7, 496-504
35. McDonald, J. K.; Leibach, F. H.; Grindeland, R. E.; Ellis, S. Purification of Dipeptidyl Aminopeptidase II (Dipeptidyl Arylamidase II) of the Anterior Pituitry Gland J. Bio.Chem. 1968, 243, 4143-4150
36. Underwood, R.; Murali, C.; Lee, H.; Schmitz, T.; Kabcenell, A. K.; Yardley, K.; Huber, B. T. Sequence, Purification, and Cloning of an Intracellular Serine Protease, Quiescent Cell Proline Dipeptidase J. Biol. Chem. 1999, 48 (26) 34053-34058
37. Aertgeerts, K.; Levin, I.; Shi, L.; Snell, G. P.; Jennings, A; Prasad, G. S.; Zhang, Y.; Kraus, M. L.; Salakian, S; Sridhar, V.; Wijnands, R.; Tennant, M. G. Structural and Kinetic Analysis of the Substrate Specificity of Human Fibroblast Activation Protein α J. Biol. Chem. 2005, 280, 19441
38. Donoghue, M.; Hsieh, F.; Baronas, E.; Godbout, K.; Gosselin, M.; Stagliano, N.; Donovan, M.; Woolf, B.; Robison, K.; Jeyaseelan, R.; Breitbart, R. E.; Acton, S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 Circ. Res. 2000, 87 (5) E1-9
39. Weber, A. E. Dipeptidyl Peptidase IV Inhibition for the Treatment of Diabetes J. Med. Chem. 2004, 47, 4135-4141
40. Abbot, C. A.; Yu, D. M.; Woollatt, E.; Sutherland, G. R.; McCaughan, G. W.; Gorrell, M. D. Cloning, Expression and Chromosomal Localization of a Novel Human Dipeptidayl Peptidase (DPP) IV Homolog, DPP8 Eur. J. Biochem. 2000, 267 (20) 6140-6150
41. Olsen, C.; Wagtmann, N. Identification and Characterization of Human DPP9, a Novel Homologue of Dipeptidyl Peptidase IV Gene 2002, 299, 185-193
42. Leiting, B.; Pryor, K. D.; Wu, J. K.; Marsilio, F.; Patel, R. A.; Craik, C. S.; Ellman, J. A.; Cummings, R. T.; Thornberry, N. A. Catalytic Properties and Inhibition of Proline-Specific Dipepetidyl Peptidases II, IV, and VII Biochem. J. 2003, 371, 525-532